Skip to Content

Ajinomoto Co Inc 2802

Rating as of

Morningstar’s Analysis

Valuation
Currency in JPY
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Ajinomoto Guiding Optimistic Outlook but Margins Boosted by Stay-at-Home Demand Unlikely To Sustain

Jeanie Chen Senior Equity Analyst

Analyst Note

| Jeanie Chen |

Narrow-moat Ajinomoto beat its full-year profit guidance as expected but the core business profits (gross profits--SG&A) slightly fell short of our forecasts due to weakness in the moaty food business. Sales decreased marginally by 0.4% year on year while business profits fell nearly 17% during the fourth quarter. Contrary to our projection of a drop in profits stemming from a tough comp and margin normalization, management guided for a slight increase in core business profits for 2021 as it expects a recovery in food service demand and price hikes will sustain profits. Despite our forecast of a 7% profit decline in 2021, we have lifted our fair value estimate to JPY 2,400, from JPY 2,200 as we rolled our forecasts and raised sales and net earnings estimates (due to a cut in the estimates of restructuring costs) mainly for 2021 and 2022. It appears the scale and impact of divestures and business restructuring on sales are less than our expectations. We continue to view shares as fairly valued with 3% upside to our fair value estimate.    

Read Full Analysis

Company Profile

Business Description

Ajinomoto is Japan’s leading food company specializing in amino acids and seasonings derived from amino-acid fermentation technologies. It also produces processed foods including dry soup mixes, frozen foods, and beverage products. Apart from the consumer business, it is a key supplier of MSG and nucleotides to global food manufacturers including Nestle. The food business represents more than three quarters of group sales and 80-plus% of profits with roughly half generated overseas. Animal nutrition, healthcare, and specialty chemicals make up the balance of its business portfolio.

Contact
15-1, Kyobashi 1-chome, Chuo-ku
Tokyo, 104-8315, Japan
T +81 352508111
Sector Consumer Defensive
Industry Packaged Foods
Most Recent Earnings Dec 31, 2020
Fiscal Year End Mar 31, 2020
Stock Type
Employees 41,528

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.